Blogs
Healthcare and Medtech Research Reports
Nov 17, 2026
Johnson & Johnson Announces Positive Phase 3 Results for CAPLYTA in Bipolar Mania Johnson & Johnson announced positive results from Study 452, the second pivotal Phase 3 trial assessing CAPLYTA (lumateperone) for the treatment of manic episodes, with or without mixed features, in adults with bipolar I di...
Read More...
Mar 02, 2026
Summary The U.S. FDA approved Vanda Pharmaceuticals’ BYSANTI (milsaperidone) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is built on the pharmacologic framework of FANAPT (iloperidone). Vanda’s stock surged nearly 40% after BYSANTI’s approval,...
Read More...
Apr 05, 2024
Fifteen years after its first FDA approval for treating schizophrenia with Fanapt (iloperidone), Vanda Pharmaceuticals has achieved another success. Fanapt is a type of antipsychotic medication that deviates from the usual and has been administered to individuals with schizophrenia for their immediate treatment fol...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper